ADAMTS12 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- ADAMTS12 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb10043
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- ADAMTS12 antibody Polyclonal Antibodies Primary antibodies
Related genes to: ADAMTS12 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- ADAMTS12 NIH gene
- Name:
- ADAM metallopeptidase with thrombospondin type 1 motif 12
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 5p13.3-p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-04-05
- Date modifiied:
- 2018-02-13
Related products to: ADAMTS12 antibody Polyclonal Antibodies Primary antibodies
Related articles to: ADAMTS12 antibody Polyclonal Antibodies Primary antibodies
- ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) family members, including ADAMTS-12, play a significant role in the breakdown of proteoglycans such as versican and neurocan. ADAMTS-12 -mediated degradation of neurocan could be relevant to neuronal plasticity, inflammatory responses, and neural tissue repair. Investigating this process may provide novel insights into the molecular mechanisms underlying neurodegenerative diseases, therefore contributing to the development of potential therapeutic strategies. The method for evaluating the neurocanase activity of ADAMTS-12 may offer a valuable tool for studying extracellular matrix remodeling in the central nervous system. The findings may contribute to the development of targeted therapies aimed at modulating the extracellular matrix integrity in neurological disorders and broaden our understanding of protease-substrate interactions in both physiological and pathological conditions. - Source: PubMed
Fontanil TaniaCal SantiagoObaya Alvaro J - Decorin was identified as the most relevant biomarker in type 2 diabetes or obesity-related diseases, but its function in gestational obesity or gestational diabetes mellitus (GDM) remains unknown. RT-qPCR or western blot were employed to validate the expression of Decorin and ADAMTS12 in the umbilical cord blood or placental tissues of the aforementioned groups. Subsequently, an LPS + high glucose-induced primary trophoblast cell model was established to verify the expression of DCN and ADAMTS12 in trophoblasts. Based on this model, silencing (si) of Decorin, or Decorin recombinant protein (DCN-r) combined with si-ADAMTS12 intervention, was performed to investigate its effects on trophoblast cell proliferation, migration, invasion, and other characteristics. Compared to the normal pregnancy group, the levels of DCN and ADAMTS12 showed an increasing trend in the gestational obesity group and the GDM group. Notably, DCN and ADAMTS12 were markedly higher in the GDM with obesity group compared to either the gestational obesity or GDM-alone groups. LPS + high glucose inhibited the migration and invasion of primary trophoblast cells while promoting increased levels of DCN and ADAMTS12. Under LPS + high-glucose intervention, DCN-r further suppressed trophoblast cell migration and invasion while enhancing ADAMTS12 expression, whereas si-DCN reversed these effects. Additionally, si-ADAMTS12 attenuated the LPS + high glucose-induced decline in trophoblast cell migration and invasion and blocked the promoting effects of DCN recombinant protein. Silencing ADAMTS12 can inhibit the promotive effect of DCN on the migration and invasion capabilities of LPS + high glucose-induced primary trophoblast cells. Clinical trial number: not applicable. - Source: PubMed
Publication date: 2026/03/24
Chen QiulingHu TaoyanLuo Hui - - Source: PubMed
Publication date: 2026/03/06
Koch Lars - Pancreatic cancer is a highly intractable malignancy that necessitates personalized treatment strategies. Conventional patient-derived models, such as three-dimensional organoids, are often limited by intellectual property constraints and high costs. In this study, we developed an affordable adherent culture system for patient-derived pancreatic cancer cells using a proprietary medium and laminin-coated dishes. Primary cultures were successfully established from 28 patients with pancreatic ductal adenocarcinoma, exceeding a 90% success rate. Validation of eight samples confirmed maintenance of epithelial cell adhesion molecule expression and preservation of oncogenic mutations. Transcriptomic profiling revealed consistent upregulation of a six-gene signature (, , , , , and ), which is associated with malignancy. In vitro drug sensitivity assays revealed interpatient heterogeneity with preliminary clinical associations. In conclusion, this simplified platform provides high-purity cancer cells and serves as a functional precision medicine tool. Beyond conventional chemotherapy, this platform has the potential to support applications ranging from biomarker validation and exploratory preclinical testing of novel therapeutics, including immune checkpoint inhibitors and antibody-drug conjugates. This optimization can lead to personalized therapeutic strategies for pancreatic cancer. - Source: PubMed
Publication date: 2026/02/07
Kato YuYamamoto NaokiUchida YuichiroHiramatsu NorikoOzeki TakatoMinobe YukariHasegawa YukikaKawabe ShoYabuuchi HikaruYamada SeijiHata YukoSugihara EijiTakimoto TetsuyaSaito KuniakiTakahara TakeshiSuda KoichiNagano OsamuSaya Hideyuki - Reliable detection of robust biomarkers from high-dimensional transcriptomic data remains a major challenge in computational oncology. Traditional approaches often suffer from overfitting and poor generalization due to the high dimensionality of genomic data and limited sample sizes. This study aims to identify an optimal, biologically meaningful subset of mRNA biomarkers capable of distinguishing ovarian cancer samples from healthy controls using an integrated machine learning-based feature selection framework. - Source: PubMed
Publication date: 2026/01/28
Thelagathoti Rama KrishnaJiang ChaoChandel Dinesh STom Wesley ASarmiento CleoKrzyzanowski GaryOlou AppolinaireFernando M Rohan